Diagnostic accuracy of glycogen phosphorylase BB for myocardial infarction: A systematic review and meta-analysis

Wearable biosensors for monitoring and as a predictive adjunct for patients at risk for ischemic cardiac-related injury

Despite increased attention and preventive efforts, the prevalence of major adverse cardiovascular events continues to rise, resulting in profound concerns for both the individual and the population at large. Rapidly evolving biotechnologies, micro-computerization, communication, and battery design have led to widespread commercial adoption, use, and dependence on smart devices, and, more recently, biosensors. Currently worn and carried, smart devices such as mobile phones and smart watches possess impressive computational and communication capabilities, monitoring a variety of biometrics such as heart rate, blood pressure, and cardiac rhythm. Several promising biomarkers have been identified that are expressed early in the development of cardiac injury. Biosensors that can assay multiple variants are now described, obviating the limitations generally attributed to dependence upon a single biomarker. Employing mathematical modeling along with intelligent learning capabilities complements and augments their potential value. Data derived from wearable multivariate biosensors linked to already worn smart devices can communicate information to protected settings with enhanced computational capability and cogency by evaluating relayed biometrics and early expressed biomarkers as well as trending data, improving sensitivity and specificity. Integrating intelligent learning capabilities can further power these efforts with beneficial impact on individuals and groups at risk, yielding great promise as monitoring and predictive adjuncts. Future derivations might, for those of particular concern, be linked to critical drug delivery and interventional systems.

Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis

The present study provides a detailed review of cardiovascular biomarkers critical for the diagnosis, prognosis, and pathophysiology of cardiovascular diseases, the leading cause of global morbidity and mortality. These biomarkers aid in detecting disease onset, progression, and therapeutic responses, providing insights into molecular mechanisms. Enzyme markers like AST, CK-MB, LDH, CA-III, and HBDH are pivotal for detecting myocardial injury during acute events. Protein markers such as CRP, H-FABP, and MPO shed light on inflammation and oxidative stress. Cardiac Troponins, the gold standard for myocardial infarction diagnosis, exhibit high specificity and sensitivity, while IMA and GPBB indicate ischemia and early myocardial damage. Peptide markers, including BNP and NT-proBNP, are crucial for heart failure diagnosis and management, reflecting ventricular stress and remodeling. Novel peptides like MR-proANP and MR-proADM aid in assessing disease severity. Lipid markers such as lipoprotein-associated phospholipase A2 and oxylipins provide insights into lipid metabolism and atherosclerosis. Inflammatory and stress-related biomarkers, including TNFα, IL-6, GDF-15, and Pentraxin 3, illuminate chronic inflammation in CVDs. Hormonal markers like copeptin and endothelin-1 highlight neurohormonal activation, while emerging markers such as ST2, galectin-3, PAPP-A, and TMAO elucidate fibrosis, remodeling, and metabolic dysregulation. The inclusion of microRNAs and long non-coding RNAs represents a breakthrough in biomarker research, offering sensitive tools for early detection, risk stratification, and therapeutic targeting. This review emphasizes the diagnostic and prognostic utility of these biomarkers, advancing cardiovascular care through personalized medicine.

Brain-Type Glycogen Phosphorylase (PYGB) in the Pathologies of Diseases: A Systematic Review

Glycogen metabolism is a form of crucial metabolic reprogramming in cells. PYGB, the brain-type glycogen phosphorylase (GP), serves as the rate-limiting enzyme of glycogen catabolism. Evidence is mounting for the association of PYGB with diverse human diseases. This review covers the advancements in PYGB research across a range of diseases, including cancer, cardiovascular diseases, metabolic diseases, nervous system diseases, and other diseases, providing a succinct overview of how PYGB functions as a critical factor in both physiological and pathological processes. We present the latest progress in PYGB in the diagnosis and treatment of various diseases and discuss the current limitations and future prospects of this novel and promising target.